RT Journal Article
T1 DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
A1 Hidalgo-Tenorio, Carmen
A1 Cortés, Luis López
A1 Gutiérrez, Alicia
A1 Santos, Jesús
A1 Omar, Mohamed
A1 Gálvez, Carmen
A1 Sequera, Sergio
A1 Jesús, Samantha Eisabeth De
A1 Téllez, Franciso
A1 Fernández, Elisa
A1 García, Coral
A1 Pasquau, Juan
AB Dolutegravir (DTG) has shown effectiveness in combination with rilpivirine in with experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The main objectives of this real-life study were to analyze the effectiveness and safety of 3TC plus DTG in virologically suppressed HIV-1 patients and to conduct a pharmacoeconomic analysis.We conducted an observational, retrospective and multicenter study of HIV+ patients pretreated for at least 6 months with ART that was then simplified to 3TC + DTG for any reason. We gathered data on viral loads (VLs) during exposure to the DT, calculating the rate with VL
YR 2019
FD 2019
LK http://hdl.handle.net/10668/14378
UL http://hdl.handle.net/10668/14378
LA en
DS RISalud
RD Apr 11, 2025